Please login to the form below

Not currently logged in
Email:
Password:

rovalpituzumab tesirine

This page shows the latest rovalpituzumab tesirine news and features for those working in and with pharma, biotech and healthcare.

AbbVie slumps on trial results for would-be blockbuster Rova-T

AbbVie slumps on trial results for would-be blockbuster Rova-T

The fall-off is no surprise given that AbbVie has spent the last few months building up expectations for antibody-drug conjugate Rova-T (rovalpituzumab tesirine), pointing to its blockbuster sales

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics